
|Videos|September 17, 2021
Dr. Matulewicz discusses underreported smoking status in GU cancer trials
Author(s)Urology Times staff
“I think the real driving factor in all of this is that collecting smoking status and tobacco use is hard. It's difficult to get this information out. It requires a lot of time; it requires energy; it requires infrastructure in the data and the electronic medical record,” says Richard Matulewicz, MD, MS.
Advertisement
In this video, Richard Matulewicz, MD, MS, explains potential factors in underreported smoking status for GU cancer patients in clinical trials. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
Practical guide to female pelvic organ–sparing radical cystectomy
3
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
4
Lina Posada Calderon, MD, provides insights on germline BAP1–associated renal cell carcinoma
5






